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The MERG1a Channel Modulates Skeletal Muscle MuRF1, but not MAFbx, Expression

ABSTRACT
Introduction. The mechanism by which the mERG1a K+ channel increases ubiquitin proteasome
proteolysis (UPP) was investigated. Methods and Results. Atrophic gastrocnemius muscles of
hindlimb suspended mice express mERG1a, MuRF1 and MAFbx genes. Electro-transfer of
mERG1a into non-suspended mouse muscle significantly decreases muscle fiber size (12.6%)
and increases UPP E3ligase MuRF1 mRNA (real time PCR; 2.1 fold) and protein (immunoblot;
23.7%), but does not affect MAFbx E3ligase expression. Neither mERG1a-induced decreased
fiber size nor mERG1a-induced increased MuRF1 expression is significantly curtailed by coexpression of inactive HR-FOXO3a, a gene encoding a transcription factor known to induce
MAFbx expression by binding directly to its promoter. Discussion. The mERG1a K+ channel
significantly increases expression of MuRF1 but not MAFbx. We explored this expression
pattern by ectopically expressing an inactive FOXO3a and showing that it is not involved in
mERG1a-mediated expression of MuRF1. These findings suggest that mERG1a does not
modulate MuRF1 expression through the AKT/FOXO pathway.

mERG Modulates MuRF Expression 3

Key Words: mERG1a; Skeletal Muscle Atrophy; Ubiquitin Proteasome Proteolysis; MuRF1;
MAFbx/Atrogin1

mERG Modulates MuRF Expression 4

INTRODUCTION
Skeletal muscle (SKM) comprises 35-45% of the human body mass and is necessary for
movement, posture, support and temperature regulation. SKM atrophy, a loss in muscle mass
and strength, can be induced by numerous stimuli: disease (e.g., cancer cachexia, sepsis,
HIV/AIDS, diabetes), injury (spinal cord damage, denervation), immobilization, fasting, ageing
and glucocorticoid treatment1,2. Muscle loss is attributable to either a decreased protein
synthesis, increased protein degradation or some combination of both of these events. The extent
to which each contributes to muscle loss varies with animal model, the evoking stimulus, study
time course and muscle fiber type2,3,4. The protein degradation that produces atrophy results
primarily from the activity of three proteolytic systems: calpains, cathepsins and the ubiquitin
proteasome pathway (UPP). It is reported that the UPP is the primary proteolytic system
involved5 and is purported to be responsible for as much as 75% of the protein degradation that
occurs during SKM atrophy1,6,7. The UPP is a multistep pathway requiring activation of an
ubiquitin protein by an ubiquitin-activating enzyme (E1) and ATP hydrolysis. The activated
ubiquitin is transferred to the ubiquitin-carrier protein (E2) which binds to an ubiquitin protein
ligase (E3 ligase) carrying a protein substrate. The E3 ligase then transfers the ubiquitin to the
targeted substrate. Once a substrate carries (a minimum of four) ubiquitin molecules, it is
degraded by the 26S proteasome1,6,7. The basic mechanistic nature of the UPP has been
described, but the specific players vary as do the signaling pathways that lead to transcription
and translation of these players. To date, two muscle specific ubiquitin E3 ligases have been
described: Muscle atrophy F-box (MAFbx/Atrogin1) and Muscle RING Finger-1 (MuRF1).
MAFbx/Atrogin-1 is a member of the SCF (Skp1, cdc53/Cullin and F-box protein) subfamily of
ligases, containing an F-box domain which serves to bind the E3 complex to a targeted
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protein8,9,10. MuRF1 belongs to the RING Finger E3 ligase subfamily which has a canonical Nterminal RING domain followed by a conserved region characteristic of the MuRF1 family and a
zinc-finger domain8,11. Expression of these E3 ligases has been shown to be variably modulated
by both the PI3K/AKT/FOXO and the IKK-/IB-/Nfkappa B (NF-B) pathways, dependent
upon animal model and the stimulus inducing the atrophic state1,2,6,7. It has recently been shown
that these two pathways are responsible for roughly half each of the muscle wasting that occurs
in immobilization-induced SKM atrophy, demonstrating that they are the main pathways
involved in this type of atrophy12.
The ether-a-gogo-related gene 1a (ERG1a) K+ channel (Kv11.1, KCNH) produces the IKr current
which is partially responsible for late phase repolarization of the cardiac action potential.
Mutations in this channel have been linked with Long QT Syndrome 2 (LQT2), a cardiac
disorder characterized clinically by a prolonged QT interval, torsade de pointes and sudden
cardiac death13. Two alternative splice variants of ERG1 have been cloned from human
(HERG1A and 1B14) and mouse (mERG1a and 1b15) cDNA libraries and high levels of ERG1a
and 1b expression have been detected in heart and brain of various mammals, including rats,
mice and humans14,15,16. In previous studies with mice, we showed that the mERG1a
homomultimeric channel is linked to SKM atrophy induced by hindlimb suspension (HS; i.e., an
unloading model) and cancer cachexia17. Specifically, we showed that: 1) mERG1a channel
protein level is upregulated in the gastrocnemius muscles (GM) of hindlimb suspended mice
experiencing atrophy relative to matched muscles in weight bearing (WB) control mice; 2)
ectopic expression of the wildtype (WT) mERG1a splice variant in SKM of WB mice induced
atrophy while co-expression of the WT and a dominant negative mERG1a subunit (DNmERG1a, G628S18) blocked atrophy in these mice; 3) ectopic expression of the DN-merg1a
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mutant in hindlimb suspended mice inhibited atrophy; 4) pharmacological block of mERG1a
inhibited atrophy in hindlimb suspended mice and increased muscle fiber cross sectional area
(CSA) in WB mice; and 5) ectopic expression of the WT mERG1a channel in mouse GM
increased UPP activity.
Here we investigate the mechanism by which mERG1a modulates the UPP. Using a mouse HS
model of atrophy, our studies begin with a time course which demonstrates that our HS model
indeed induces increased expression of the mERG1a gene and also genes encoding the E3 ligases
MuRF1 and MAFbx while, interestingly, electro-transfer17,19 of mERG1a into mouse GM induces
expression of the MuRF1, but not the MAFbx gene. These results are confirmed with
immunoblot studies showing that MuRF1 and Atrogin1 (MAFbx protein product) protein levels
are increased in response to HS, but that only MuRF1 protein levels increase in response to
ectopic expression of mERG1a. We confirm that mERG1a expression is not modulating MAFbx
transcription by ectopically co-expressing mERG1a and a MAFbx/Atrogin1 luciferase reporter20
and showing that mERG1a expression does not increase MAFbx promoter-driven luciferase
activity levels. Additionally, we co-expressed mERG1a and FOXO3a, a transcription factor
shown to induce expression of both MAFbx and MuRF1 genes in some models of atrophy20,21,
and demonstrate that mERG1a expression does not modulate MuRF1 (or MAFbx) transcription
through FOXO3a expression.
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MATERIALS AND METHODS
Animals. All procedures were approved by the Purdue Animal Care and Use Committee. Seven
to eight week old ND4-Swiss Webster male mice (Harlan-Sprague; Indianapolis, IN) were used
in all procedures. Animals were housed in Purdue University facilities on a 12 hour light/dark
cycle, monitored by lab animal veterinarians and provided food and water ad libitum.
Hindlimb Suspension (HS). Custom suspension cages were constructed as described
previously22. Mice were placed in these cages resting in approximately a 30 head down tilt with
their hindlimbs elevated so that they were unable to place any load on their hindlimbs. Control
mice were kept in commercial mouse cages in a normal weight bearing state.
Tissue Sectioning, Staining and CSA Determination. GMs were embedded, cryo-sectioned (12
m) and stained for β–galactosidase (lacZ) activity as described earlier17. Images of sections
were captured with a Leaf Micro–Lumina digital camera (Scitex; Tel-Aviv, Israel). The CSA
(m2) of each muscle fiber was determined using Image J (NIH; Bethesda, MD).
Plasmids. The mERG1a clone in pBK/CMV15 and the dominant negative mERG1a (DNmERG1a) clone in pBK/CMV18 were generous gifts from Dr. Barry London (Cardiovascular
Institute, University of Pittsburgh, PA). The CMV-lacZ in pNL vector was purchased from the
Center Commercial de Gros (Toulouse, France). The phRL synthetic Renilla luciferase reporter
vector was purchased from ProMega (Madison, WI). The MAFbx/Atrogin1 luciferase reporter
was generously provided by Dr. Stewart Lecker (Beth Israel Deaconess Medical Center, Boston,
MA20). The HR-FOXO3a (H212R) plasmid, a mutated form of FOXO3a which is inactive
because of its inability to bind DNA, was developed in the laboratory of Dr. Naoya Fujita
(Japanese Foundation for Cancer Research, Japan23).
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Electro-transfer. Mice were anesthetized with 10 l/g body weight of a solution of xylazine (1
mg/ml) and ketamine (9 mg/ml) in sterile saline. GMs of shaved hindlimbs were injected with
expression plasmids in 50 l sterile saline and electroporated with 8 pulses at 200V/cm for 20 ms
at 1 Hertz with an ECM 830 ElectroSquare Porator (BTX; Hawthorne, NY). This method has
been shown to result in gene transcription and translation in SKM in our laboratory17,19.
Real time PCR. Trizol reagent (Invitrogen; Carlsbad, CA) was used to extract total RNA from
SKM according to manufacturer’s instructions. The extraction was followed sequentially by
phenol/chloroform extraction and ethanol precipitation. Any contaminating DNA was degraded
by two 10 min treatments with DNase I (ProMega; Madison, WI). DNase was then heat
inactivated. SYBR Green Supermix with Rox (Applied Biosystems; Foster City, CA) was added
to the PCR reaction (per manufacturer’s instructions) and finally primers (see Table 1) for the
gene of interest were added to the samples (in triplicate) while primers for an appropriate
“housekeeping” gene (the 18S ribosomal subunit) were added to duplicate samples (in triplicate).
A 7300 Real Time PCR System (Applied Biosystems) was used to detect SYBR Green
fluorescence as a measure of amplicon. Sample CT values were normalized to (subtracted from)
the CT values of the “housekeeping” gene and the number 2 was raised to a power equal to the
difference between the sample CT values of the 18S subunit and the gene of interest.
Dual Luciferase Reporter Assay. The Dual-Luciferase Reporter Assay Kit (Promega; Madison,
WI) was used in accordance with manufacturer’s instructions. Firefly luciferase and Renilla
luciferase activities were measured with a TD-20/20 Luminometer (Promega, WI).
Western Blot. GMs were homogenized in Tris buffer (10 mM, pH 7.4) containing 1 mM EDTA
and protease inhibitors (0.5 mM Pefabloc, 1 uM pepstatin A and 1 mM of each benzamidine and
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iodoacetamide; Sigma-Aldrich, St. Louis, MO). The homogenates were centrifuged at 1000xg
for 10 minutes and the supernatants were collected and the protein contents were determined
using a DC Protein Assay Kit (Bio-Rad; Hercules, CA) according to manufacturer’s instructions.
Samples were immunoblotted basically as described earlier16,17: protein samples (40 g) were
electrophoresed through 4-20% acrylamide gels, transferred to PVDF membrane (BioRad;
Hercules, CA) and immunoblotted using Atrogin1 and MuRF1 antibodies (ECM BioSciences;
Versailles, KY) and an ImmunStar Western Chemiluminescent Kit (Bio-Rad). Optical densities
of protein bands were determined using ImageJ (NIH) software.
Study Designs.
Study 1. Eight groups of seven mice each were hindlimb suspended22 for either 1,2,3,4,5,7,10 or
14 days while another group of 7 weight bearing animals were used as day 0 controls (n=63).
After the assigned control or suspension duration, each group of mice was killed according to the
approved protocol and the GMs were harvested and flash frozen in liquid nitrogen. The left
GMs from all mice were prepared for real time PCR and thus assayed for expression of
mERG1a, MuRF1 and MAFbx. Normalized sample CT values for the Day 0 control were
averaged and the fold increase in gene expression for each gene per mouse was determined by
calculating the ratio of each daily sample mouse value to the average Day 0 value.
Study 2. The left legs of 30 (6 groups of 5) mice were injected with 10 g lacZ and 20 g empty
control expression plasmid whereas the right legs were injected with a combination of 10 g
lacZ and 20 g mERG1a expression plasmid and all legs were subjected to electrotransfer. A
group of 5 mice each was killed at 1,2,3,4,5 and 6 weeks each after electrotransfer and the GMs
from all legs were harvested and flash frozen in liquid nitrogen. The muscles were cryo-
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sectioned and stained for lacZ activity as a marker for gene expression. Because a greater
abundance (2X) of mERG1a than lacZ cDNA was injected, we assume that all myofibers
staining for lacZ reporter activity also express mERG1a and that those myofibers not staining for
lacZ activity are not expressing plasmid.
Study 3A. The left GMs of 49 mice (7 groups of 7) were injected with plasmid encoding lacZ
(10 g) and a second plasmid encoding mERG1a (30 g) while the right GMs were injected with
the lacZ plasmid (10 g) and an empty (control) plasmid (30 g), followed by electro-transfer.
Seven mice were killed immediately to give a Day 0 data point. Seven more mice were killed at
days 1,2,3,4,5 and 7 each post electro-transfer. RNA was extracted from GMs and real time
PCR was used to determine expression levels of mERG1a, MuRF1 and MAFbx. CT values were
normalized (see methods) and the left (mERG1a treatment) to right (control) leg gene expression
ratio was determined for each mouse as an indicator of treatment effect. Expression ratios for
the Day 0 control were averaged and the fold increase in gene expression for each gene was
determined by calculating the ratio of each daily sample mouse value to the average Day 0 value
(baseline).
Study 3B. Ten mice were anesthetized and (as control) the GMs of both legs were injected with:
1) plasmid encoding the Renilla luciferase reporter (10 g), 2) the MAFbx/Atrogin1 luciferase
reporter plasmid (20 g), and 3) an empty plasmid (20 g). The right GMs of another 10 mice
were injected as above while the left legs received the same mixture except that mERG1a
plasmid (20 g) was injected instead of the empty plasmid. Seven days after electrotransfer, the
GMs were harvested and flash frozen in liquid nitrogen. These were later homogenized and
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assayed for Renilla and firefly luciferase activities using a Dual Luciferase Reporter Kit
(ProMega).
Study 4. Hindlimb suspension. Two groups of 3 mice each (n=6) were: 1) allowed to remain
weight bearing; or 2) hindlimb suspended. After 7 days of treatment (day 7 is when our model
induces significant levels of myofiber CSA decrease17), the mice were killed and the GMs were
harvested and used to prepare muscle protein samples (both muscles of one mouse composed a
sample). Electro-transfer. The GMs of a group of 6 mice (n=6) were injected with DNA (left =
10 g lacZ and 30 g mERG1a; right leg = 10 g lacZ and 30 g empty control plasmid) and the
legs were electroporated. Two muscles were combined to make a sample; that is, two left legs
made one mERG1a treated sample and two right legs composed a control sample, etc. GMs of
mice from both designs were homogenized and centrifuged as described. Aliquots of each
protein sample were electrophoresed and immunoblotted with either MuRF1 or Atrogin1
antibody.
Study 5. Mice (n=56) were randomly assigned to 4 groups (of 16 each), anesthetized and the left
GMs were injected with expression plasmid: 1) lacZ (10 g) and empty plasmid (40 g); 2) lacZ
(10 g), empty (20 g) and mERG1 (20 g); 3) lacZ (10 g), empty plasmid (20 g) and HRFOXO3a (20 g); and 4) lacZ (10 g), mERG1 (20 g) and HR-FOXO3a (20 g). All right
GMs received lacZ (10 g) and control plasmid (20 g) and all GMs were electroporated. After
7 days, the muscles of 28 mice were assayed for mERG1a, HR-FOXO3a, MuRF1 and MAFbx
expression by real time PCR and the fold increase in gene expression of left leg over right leg
was calculated for each mouse. The muscle fiber CSAs were measured in the GMs of the
remaining 28 mice.
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Statistics. Data were analyzed using either ANOVA or a Student’s t-test as reported in the figure
legends. When ANOVA was used, data were analyzed for a completely randomized design.
When significant differences were found, means were separated by Fisher's Protected Least
Significant Difference. All data were analyzed using the General Linear Model Procedure of
SAS (SAS Institute Inc.; Cary, NC). Statements of significance are based on p levels as noted in
legends.
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RESULTS
Study 1. Hindlimb suspension induces mERG1a, MuRF1 and MAFbx gene expression in the
GMs of mice. Rationale. To aid in design of an optimal time course for our mERG1a ectopic
expression model, we determined the time course of expression for mERG1a, MuRF1 and
MAFbx genes in response to HS. Data. Real time PCR results show that mERG1a, MuRF1 and
MAFbx genes were all expressed in response to HS (Fig. 1). Increases in MAFbx mRNA levels
are noted as early as Day1 and continue to increase steeply to reach a maximum at Day 4.
MAFbx mRNA levels begin to decline after Day 4 and expression of this gene is back to Day 1
levels between Days 7 and 10. mERG1a mRNA levels show a humble rise at Day 3 (Fig. 1,
inset) just prior to a rise in MuRF1 mRNA levels, which increase sharply between Days 3 and 4
(Figure 1, inset). MuRF1 mRNA levels peak at Day 4 and then drop to initial levels between
Days 7 and 10 while mERG1a mRNA levels peak at Day 5 before dropping to initial levels also
between Days 7 and 10.
Study 2. Electrotransfer of expression plasmid into mouse GM yields gene transcription and
translation with significant results lasting up to one month. Rationale. To support the validity of
our studies reporting responses (over time) to electrotransfer of expression plasmid into skeletal
muscle, we conducted a long term study of changes in GM CSA in response to mERG1a
expression. Data. Indeed, as reported earlier17, the myofiber CSA was significantly decreased in
the myofibers of the mERG1a injected legs expressing plasmid relative to the myofibers in the
same leg not expressing plasmid and to both the expressing and non-expressing myofibers in
muscles injected with lacZ and empty plasmid (Fig. 2). The decrease in fiber size is attributable
to mERG1a expression and is significant for 4 weeks; the mERG1a expressing myofiber CSAs
are no longer significantly smaller than controls at 5 and 6 weeks after electrotransfer.
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Study 3. MuRF1, but not MAXbx, gene expression occurs within the GMs of mice in response to
ectopic expression of mERG1a. A. Rationale. To isolate responses to mERG1a expression, we
ectopically expressed mERG1a in GMs of mice and assayed for mRNA of interest over time to
ensure that we did not miss changes in expression of the E3 ligase genes. Data. Real time PCR
results show that indeed mERG1a was expressed in response to mERG1a plasmid electrotransfer in the GMs (Fig. 3A). Importantly, the MuRF1 E3 ligase gene was also expressed in
response to the mERG1a expression and, although no significant differences from baseline
transcript levels were detected at Days 1 or 2 post electrotransfer (Fig. 3A), the data reveal that
mERG1a and MuRF1 transcript levels both increased above Day 1 levels significantly by Day 3
and peaked at Day 4. Transcript levels for both genes declined toward baseline levels by day 7.
The data indicate that MuRF1 expression is increased by ectopic mERG1a expression. Most
interestingly, there is no significant increase in MAFbx gene expression over the 7 days during
which mERG1a was expressed, suggesting that ectopic expression of mERG1a did not activate
this potential route for protein degradation. B. Rationale. To confirm that mERG1a expression
does not affect MAFbx expression, we co-expressed mERG1a, a MAFbx luciferase reporter and a
Renilla luciferase reporter (as control for differences in transfection efficiencies) and assayed for
dual luciferase activities 7 days later. Data. The ratio of firefly to Renilla luciferase activities
was determined for each leg and the ratio of luciferase activity in the left to right legs was
calculated for each mouse (Fig. 3B). Although mice from a set of positive controls showed that
mERG1a expression decreases levels of ubiquinated firefly luciferase (data not shown), in
concert with expectations, MAFbx/Atrogin1 reporter luciferase activity was not significantly
affected by mERG1a co-expression (Fig. 3B). These studies confirm that mERG1a expression
does not affect MAFbx expression.
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Study 4. MuRF1 protein levels increase in response to HS and ectopic expression of mERG1a
while Atrogin1 protein levels increase in response to HS only. Rationale. Because increased
mRNA expression is not always an indicator of augmented protein synthesis (nor can it be
equated with increased protein activity), we assessed levels of MuRF1 and Atrogin1 proteins in
GMs from both hindlimb suspended mice and those ectopically expressing mERG1a using
western blots. Data. Both visual observation and optical density data show that MuRF1 protein
(~37 kDa) levels increase over controls in the GMs of both HS mice and those ectopically
expressing mERG1a (Fig. 4A and C, respectively); however, Atrogin1 protein (~41 kDa) levels
increase only in response to HS (Fig. 4B,D). The Coomassie stained membranes confirm that
equal amounts of protein were loaded into the lanes. These data further demonstrate that
mERG1a expression induces transcription and translation of MuRF1, but not MAFbx.
Study 5. Block of FOXO3a DNA binding does not inhibit mERG1a up-regulation of MuRF1.
Rationale. To test if MERG1a modulates MuRF1 expression through FOXO3a, we expressed a
mutant form of FOXO3a (HR-FOXO3a, unable to bind DNA23) ± mERG1a in WB mice and then
assayed for atrophy. If the mERG1a K+ channel modulates MuRF1 expression through the
FOXO3a transcription factor, then inhibition of active FOXO3a DNA binding will lower MuRF1
mRNA levels and diminish the changes in myofiber CSA shown to occur in response to
mERG1a expression17. Data. The fold increase in mERG1a and FOXO3a mRNA levels in
muscles injected with each respective expression plasmid shows that transcripts were made (Fig.
5A). The data also show that the MuRF1 mRNA level was significantly increased in response to
mERG1a expression and confirm that MAFbx levels are not affected by mERG1a expression or
by the levels of MuRF1 expression reached in this experiment. It further shows that mERG1a
expression did not result in increased levels of FOXO3a transcription because our primers would
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have detected this native mRNA. Although statistically insignificant, the fold increases in
MAFbx transcript do “creep” above 1.0, hinting that the HR-FOXO3a could be inhibiting some
basal level of MAFbx transcription. Most interestingly, there was no significant change in the
levels of mERG1a-induced MuRF1 mRNA transcribed in the presence of HR-FOXO3a as would
be expected if mERG1a modulated MuRF1 transcription through FOXO3a (Fig. 5A). Muscle
fiber CSA data demonstrate that, indeed, muscle fiber size decreases in response to mERG1a
expression; however, this decrease in muscle fiber CSA is not affected by expression of HRFOXO3a (Fig. 5B). These sets of data suggest that mERG1a does not modulate
MuRF1expression through FOXO3a activity. Verification: To ensure the validity of experiments
performed with HR-FOXO3a, we determined that the HR-FOXO3a plasmid functions as a
dominant negative when ectopically expressed in mouse GM. We ectopically expressed empty
control plasmid (40 g) in the right legs of 20 mice. The left legs of 10 of these mice received
the same plasmid as control while another group of 10 received HR-FOXO3a (40 g) in their left
legs. All mice were hindlimb suspended. After 4 days, we harvested the GMs and determined
the MAFbx mRNA expression levels using real time PCR and analyzed the data to yield ratios of
MAFbx mRNA expression in left to right legs. As expected, HS resulted in increased MAFbx
expression over weight bearing controls. The ratio of MAFbx mRNA expression in the control
mice (left over right leg) was 1.06 ±0.06 while the ratio was 0.8±0.08 (p≤0.05) in the mice
receiving the HR-FOXO3a plasmid in their left legs, indicating the inactive HR-FOXO3a
interfered with transcription of MAFbx in muscle of HS mice as would be expected.
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DISCUSSION
In earlier work, we showed that the mERG1a K+ channel is up-regulated in atrophic GM from
hindlimb suspended mice in contrast to muscle from weight bearing control animals and that
mERG1a up-regulates UPP activity17. The mechanism(s) by which mERG1a modulate(s) UPP
activity are unknown. We hypothesize that mERG1a acts upstream of pathways already known
to modulate the UPP in SKM atrophy. For example, it has been shown that deactivation of the
PI3K/AKT1/FOXO pathway and/or activation of the IKK-/IB-/NF-B pathway can upregulate UPP activity in atrophic SKM mainly by modulating expression of “atrogenes” (i.e.,
genes up-regulated during muscle loss). Particularly, these pathways have been shown to upregulate genes which encode the SKM specific E3 ligases, MuRF1 and Atrogin11,2,7. In fact,
recent studies demonstrate that both FOXO and NF-B transcription factors are up-regulated in
many atrophy models (including unloading)20,24-26 and one particularly elegant study by Reed
and colleagues demonstrates that each of these transcription factor families is responsible for
roughly 50% of the muscle loss occurring in immobilization-induced atrophy12. Here we report
that hindlimb suspension induces atrophy and up-regulates expression of mERG1a, MuRF1 and
MAFbx genes and, interestingly, that ectopic expression of the mERG1a K+ channel in mouse
GM increases expression of the MuRF1 gene, but not that of the MAFbx gene. We hypothesize,
therefore, that although mERG1a could act on MuRF1 gene expression through a novel pathway,
it likely modulates MuRF1 expression by a pathway currently known to modulate E3 ligase
expression.
PI3K/Akt/FOXO: In general, deactivation of PI3K (phosphoinositide 3-kinase) results in
reduced Akt phosphorylation and, thereby, deactivation of this enzyme. Once deactivated, Akt
no longer phosphorylates FOXO transcription factors; the dephosphorylated/activated FOXO
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(three isoforms have been described in SKM: FOXO1, 3 and 4) then moves to the nucleus and
promotes transcription of MAFbx and/or MuRF-1 and other known atrogenes1,2,7. Research with
diabetes–induced muscle atrophy suggests that UPP activity is increased by suppressed PI3K and
Akt activities with concomitant increased FOXO1 phosphorylation and resultant increases in
MAFbx and MuRF1 mRNA levels27-29. In dexamethasone treated C2C12 myotubes, it has been
shown that FOXO1 does not increase MuRF1 or MAFbx transcription directly, but does so
indirectly by inhibiting the IGF-1 block of their upregulation30. It has been demonstrated that
FOXO3a expression results in increased levels of MuRF1 mRNA31 in cardiomyocytes and also
induces the transcription of MAFbx20. In immobilization studies, upregulation of MAXbx and
MuRF1 expression occurs in numerous species including mice32 and rats8,33. Unloading studies
in humans also reveal changes in MuRF1 and MAFbx expression34 and show that these changes
differ according to which muscle is monitored and suggest, therefore, that E3 ligase expression
may be fiber type specific4,35. Nonetheless, the mechanism(s) responsible for these changes in
E3 ligase abundances are not well understood.
Here we show that hindlimb suspension induces expression of mERG1a, MuRF1 and MAFbx. In
fact, transcription of all the assayed genes occurs early in HS, prior to Day 7, at which time
muscle fiber CSA is significantly smaller than in control WB mice17. However, while MuRF1
mRNA levels are correlated with mERG1a expression, MAFbx mRNA levels begin to rise prior
to any noted increase in mERG1a mRNA levels, suggesting that at least initial MAFbx gene
expression is likely not linked to HS induced mERG1a expression. Importantly, we demonstrate
that ectopic expression of mERG1a indeed induces expression of MuRF1 in mouse GM. In fact,
MuRF1 expression mirrors that of electro-transferred mERG1a very closely, with mERG1a
levels rising at day 3 prior to a sharp increase in MuRF1 mRNA levels between Days 3 and 4.
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These data suggest that the increase in MuRF1 expression is likely subsequent to the day 3 rise in
mERG1a transcript. Interestingly, data also show that mERG1a expression does not induce
MAFbx transcription. This is most interesting because this isolation of mERG1a-expression
effects reveals a separation of E3 ligase modulation at the level of a membrane protein. Because
it has been shown that FOXO3a induces expression of MAFbx specifically by binding directly to
the MAFbx promoter in mouse muscle21, our data suggest that mERG1a does not modulate
FOXO3a gene expression or protein activity. To test if mERG1a affects MuRF1 expression
through FOXO3a, we co-expressed mERG1a and an inactive FOXO3a (HR-FOXO3a). We
found that inhibition of FOXO3a activity (i.e., DNA binding) did not diminish changes shown to
occur in response to mERG1a expression; that is, it did not lower MuRF1 mRNA levels or
prevent the decrease in muscle fiber CSA seen in mERG1a treated controls. Further, our studies
reveal that mERG1a expression does not modulate FOXO3a mRNA levels. Therefore, we
conclude that MERG1a does not induce MuRF1 transcription through up-regulation of FOXO3a
expression. Further, we suggest that it is not likely that MERG1a induces FOXO3a activity
(increased inhibition of its phosphorylation or increased dephosphorylation) mainly because
MAFbx mRNA levels do not increase with mERG1a expression as would be expected if
FOXO3a activation were augmented and translocation to the nucleus were up-regulated. (Of
course, our data does not rule out the possibility that mERG1a up-regulation of MAFbx
transcription requires some MAFbx promoter specific co-factor not present in this model, but
present during HS, which would allow FOXO3a to bind the MAFbx promoter.) It still remains to
be definitively determined if the mERG1a channel modulates MuRF1 expression through the
FOXO transcription factor family. We suspect that mERG1a does not affect FOXO factors
because: 1) it does not modulate MAFbx expression (and it has been shown that FOXO 1 and 4
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can modulate MAFbx expression in some models30,36); and 2) increasingly research suggests that
MAFbx expression is modulated by FOXO transcription factors while MuRF1 expression is
regulated by NF-kB factors20,21,36,37. Nonetheless, further studies with mutant forms of FOXO1
and FOXO4 should be performed to determine definitively that mERG1a is (or is not) inducing
MuRF1 expression through these transcription factors. If FOXO family members are implicated,
then studies determining if Akt and PI3K are involved will be required.
Other recent work reports that treatment of rat skeletal muscle with PPAR- agonist yields
decreased PI3K/Akt signaling activity, increased FOXO1 transcription factor activity and
concomitant increases in MuRF1 and MAFbx expression38. If mERG1a is increasing MuRF1
production by inactivating some point of the PI3K/Akt pathway, then it could be acting through
effects of PPAR- agonists on the membrane-bound PPAR- receptors. Of course, the work
does not address potential effects on other pathways (e.g., NF-B factors), so it does not rule out
that PPAR- activation is increasing MuRF1 (or MAFbx) expression through other activity(-ies).
PI3K/Akt independent mechanisms also have been shown to modulate FOXO activity. For
example, Nemo-like kinase (NLK) has been shown to bind and phosphorylate FOXO1, thereby
inhibiting its transcriptional activity through the PI3k/Akt independent transforming growth
factor-beta-activated kinase (TAK1)-NLK pathway39. Further, Atrogin1 expression has been
shown to be induced by a p38MAPK dependent pathway in cardiac myocytes, independent of
the Akt/FOXO pathway40. These routes represent further possibilities for mERG1a modulation
of MuRF1 expression.
IKK-/IB-/NF-B: Activation of NF-B family members by upstream IKK- activation
leads to production of E3 ligases2,24,37,41. In brief, some factor triggers activation of IKK-
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(kinase) by phosphorylation. In cachectic atrophy, evidence suggests that activation of tumor
necrosis factor alpha receptors triggers this step, but this does not appear to be the case with
atrophy induced by unloading. In both cases, however, active IKK- phosphorylates IBwhich is then ubiquitinated and degraded, releasing bound NF-B factors. Different NF-B
factors are released dependent upon what triggers the atrophy1. In unloading atrophy, it has been
shown that levels of p50 (NF-B factor) and Bcl-3 (an IB family member) increase with
atrophic conditions and, in fact, the decrease in SKM size caused by hindlimb suspension is
ameliorated in both p50 and Bcl-3 knockout mice26. Once released, the NF-B proteins then
translocate to the nucleus and cause transcription of numerous genes, including MuRF1, but
interestingly, not MAFbx37,41. We suggest, in fact, that because ectopic expression of mERG1a
induces an increase in MuRF1 (and not MAFbx) mRNA and protein levels, that mERG1a would
modulate (increase) the expression and/or activity of upstream NF-B transcription factors.
Nonetheless, given that mERG1a expression causes a significant increase in MuRF1 mRNA and
protein levels and the fact that NF-B factors are known to be involved in MuRF1 expression,
the data suggest that mERG1a could modulate NF-B factor expression and/or activity.
Identifying if/which NF-B factors are modulated by mERG1a and the mechanism(s) by which
this occurs clearly requires study.
In summary, we present data which show that MuRF1 gene expression is significantly increased
in response to mERG1a expression and confirms that MAFbx expression is not affected by
mERG1a expression or by the levels of MuRF1 reached in these experiments. That is, we have
shown what appears to be a complete separation of MuRF1 and MAFbx/Atrogin1 E3 ligase
modulation at the level of a membrane protein. Further, we demonstrate that MuRF1 modulation
by mERG1a is not occurring through FOXO3a. Considering our data, this latter conclusion is
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not surprising given the facts that NF-B is basically required for disuse muscle atrophy27,37,42
and that MuRF1 transcription, and not MAFbx, is increased by NF-B factors37. Obviously, the
mechanism by which the mERG1a K+ channel up-regulates MuRF1 expression in SKM needs
further investigation along with the factors inducing up-regulation of the K+ channel itself.
Investigation of the mechanism(s) initiating SKM atrophy is important because SKM atrophy is
coincident with many pathological conditions and is related to increased disability, morbidity
and mortality and understanding these pathways will suggest specific, more effective therapies
for abatement of this debilitating condition.
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ABBREVIATIONS
SKM - skeletal muscle
UPP - ubiquitin proteasome proteolysis
E3 ligase - ubiquitin protein ligase
MAFbx - Muscle atrophy F-box
MuRF1 - Muscle RING Finger-1
SCF - Skp1, cdc53/Cullin and F-box protein
NF-B – Nfkappa B
ERG1a – ether-a-gogo-related gene 1a
mERG1a - mouse ether-a-gogo-related gene 1a
HERG1A – human ether-a-gogo-related gene 1A
HS - hindlimb suspension
GM – gastrocnemius muscle
WB – weight bearing
WT - wildtype
DN-mERG1a - dominant negative mERG1a
CSA - cross sectional area
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lacZ – -galactosidase enzyme
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Target Gene

TM oC

Forward Primer

Reverse Primer

Amplicon

mERG1a

60

5'–CGC AGA ACA CCT

5'–GCA GAA GCC GTC

119 bp

TCC TCG ACA C-3'

GTT GCA GTA G-3'

5’–GGG CTA CCT TCC

5’–ACT CCT CCT CCT

TCT CAA GTG–3’

CCT CAT CTG–3’

5’–CGT CGC AGC CAA

5’–ATC CAG GAT GGC

GAA GAG AAA G–3’

AGT CGA GAA G–3’

70 f;

5’-AAA TGT TCG TCG

5’–GTC GCC CTT ATC

60 r

CGG CGG AAC-3’

CTT GAA GTA–3’

18S

57 f;

5’–CGG CTA CCA CAT

5’–GCT GGA ATT ACC

(ribosomal)

58 r

CCA AGG AA–3’

GCG GCT–3’

55

MuRF1

55

MAFbx

FOXO3a

Table 1. Forward and reverse primers used for real time PCR.

183 bp

171 bp

153 bp

123 bp
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Figure 1. Hindlimb suspension (HS) induces mERG1a, MuRF1 and MAFbx gene expression in
the gastrocnemius muscle of mice. Real time PCR demonstrates that HS induces highest
expression of mERG1a, MuRF1 and MAFbx genes soon after commencement of suspension.
Each daily data point was compared to the average day 0 level (day X/day 0) to yield a fold
increase per mouse; fold increase per mouse data were averaged per day. Data points are,
therefore, mean fold increase in gene expression (± standard deviation) over time. Inset:
mERG1a and MuRF1 gene expression is graphed using a smaller y-axis to better show response
to time course. Within gene, all data were analyzed by ANOVA (see methods). The “*”
indicates a significant (p<0.05) increase in gene expression over the day 0 control within gene. 7
mice/day, n=63 mice.
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Figure 2. Electrotransfer of mERG1a and the lacZ reporter expression plasmids into
gastrocnemius muscle (GM) yields results lasting 4 weeks. Relative to fibers of muscles injected
with mERG1a and -galactosidase (lacZ), but not expressing lacZ activity (MN), the cross
sectional areas of the fibers injected with mERG1a and expressing lacZ activity (ME) are
significantly decreased in weeks 1 through 4. The areas of the ME fibers are also significantly
smaller than lacZ expressing (LE) and non-expressing (LN) fibers of GMs injected with lacZ
only. There are no significant differences in fiber cross sectional area after 4 weeks. All data
were analyzed by ANOVA (see methods). Statements of significance (“*”) were based on
p<0.05. n=30 mice.
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Figure 3. MuRF1, but not MAFbx, gene expression occurs within mouse gastrocnemius muscles
(GM) in response to mERG1a expression. A. mERG1a and MuRF1 mRNA levels increase in
response to mERG1a electro-transfer. Methods. Left GMs were injected with -galactosidase
(lacZ) and mERG1a plasmids; right GMs received lacZ and empty plasmid. After electrotransfer, GMs from 7 mice were harvested each day at days 0-5,7 and assayed with real time
PCR. Data represent mean (± standard deviation) fold increase in daily gene expression over
average day 0. Within gene, data were analyzed by ANOVA (see methods). The “*” indicates
significant (p<0.05) increase in expression over day 0 within gene. 7 mice/day, n=49. B.
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mERG1a expression in GM does not modulate MAFbx. Right GMs (n=20) were injected with:
1) Renilla luciferase reporter, 2) MAFbx/Atrogin1 luciferase reporter and 3) empty plasmid. Left
GMs were treated identically except they received mERG1a instead of empty plasmid. Seven
days post electro-transfer, GMs were assayed using a Dual Luciferase Reporter Kit (ProMega).
The ratio of firefly to Renilla luciferase activities was determined per leg and activity ratios (left
to right legs) were calculated per mouse. Data were analyzed by Student’s T-test (SAS) and
represent mean ± standard deviation; p<0.55.
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Figure 4. Immunoblots demonstrate that MuRF1 protein levels in gastrocnemius muscles (GMs)
increase in response to both hindlimb suspension (HS) and ectopic expression of mERG1a while
Atrogin1 protein levels increase in response to HS only. Protein samples (40 g) from GMs
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were electrophoresed through 4-20% acrylamide gels, transferred to PVDF membrane (BioRad;
Hercules, CA) and immunoblotted with antibody recognizing either MuRF1 or Atrogin1 protein
(ECM BioSciences; Versailles, KY). A and B. In both immunoblots (top), lanes 1-3 contain
control GMs while lanes 4-6 contain GMs from mice suspended for 4 days. MuRF1 (A) and
Atrogin1 (B) protein levels increased significantly (434% and 222%, respectively) in response to
HS. C and D. In both immunoblots (top), lanes 1-3 contain GMs electro-transferred with
mERG1a while lanes 4-6 contain GMs electro-transferred with control plasmid. MuRF1 protein
levels (C) increased significantly (156%) while the increase (115%) in Atrogin1 protein
abundance (D) is not significant. A-D. Coomassie stained membranes (below immunoblots)
show that equivalent levels of protein were loaded into the lanes. Data were analyzed by
Student’s T-test (SAS). Bars represent the mean (± standard deviation) optical density units of
proteins as determined by ImageJ (NIH). The p values are noted in the graphs.
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Figure 5. mERG1a-induced up-regulation of MuRF1 expression is not inhibited by block of
FOXO3a DNA binding. We expressed HR-FOXO3a (an inactive mutant unable to bind DNA) ±
mERG1a in mouse gastrocnemius muscle (GM) and assayed for atrophy: A. E3 ligase
expression; and B. muscle fiber cross sectional area (CSA). Figure A. Real time PCR indicates
that the increase in MuRF1 mRNA levels noted in response to mERG1a expression is not
curtailed by co-expression of HR-FOXO3a. Further, ectopic mERG1a expression does not affect
levels of FOXO3a nor MAFbx mRNA. Data were analyzed by ANOVA (see methods) and are
expressed as group mean ± S.E.M. Different letters indicate significant differences, p≤0.05;
n=28 mice. Figure B. The decrease in muscle fiber CSA that occurs in response to mERG1a
expression is not affected by co-expression of HR-FOXO3a. GMs were injected with expression
plasmids: 1. control and -galactosidase (lacZ); 2. control, lacZ and mERG1a; 3. control, lacZ
and HR-FOXO3a; and 4. lacZ, mERG1a and HR-FOXO3a. Seven days after electro-transfer,
muscle cryo-sections were stained for lacZ reporter to indicate plasmid expression. Data were
analyzed by ANOVA (see methods). Bars represent mean CSA ± S.E.M. Statistical differences
are noted by ”*”, p≤0.01. n=28. Scale bar = 40 m.

